首次脱髓鞘事件后年龄相关残疾结局
该前瞻性队列纳入1994年以来18-50岁首次脱髓鞘事件患者1170例,按年龄分组比较残疾结局。40-50岁组炎症活动指标风险较低,但确认残疾累积、独立于复发活动的进展及EDSS 3.0风险较高。
要点
- 40-50岁组首次脱髓鞘事件时复发相关恶化比例高于30-39岁和18-29岁组。
- 40-50岁组达到McDonald 2017标准、首次复发等炎症结局风险低于18-29岁组。
- 40-50岁组确认残疾累积、独立于复发活动的进展风险高于18-29岁组。
核心结论
- 40-50岁发生首次脱髓鞘事件的患者炎症性结局较少,但残疾进展风险更高。
研究设计与样本
- 前瞻性队列研究,1994年起纳入18-50岁首次脱髓鞘事件3个月内评估的患者,共1170例,中位年龄32岁,女性69%。
主要发现
- 40-50岁组首次脱髓鞘事件时复发相关恶化比例为34%,30-39岁组为25%,18-29岁组为29%(p=0.031)。
- 40-50岁组EDSS年增长较18-29岁组更高(β 0.019,95%CI 0.0001-0.0387)。
- 40-50岁组较18-29岁组达到McDonald 2017标准风险更低(HR 0.80,95%CI 0.67-0.96)。
- 40-50岁组较18-29岁组首次复发风险更低(HR 0.59,95%CI 0.47-0.74),复发相关恶化风险更低(HR 0.51,95%CI 0.31-0.86)。
- 40-50岁组较18-29岁组确认残疾累积风险更高(HR 1.49,95%CI 1.16-1.97),独立于复发活动的进展风险更高(HR 2.48,95%CI 1.88-3.27),EDSS 3.0风险更高(HR 1.50,95%CI 1.05-2.12)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Emerging concepts in the early detection of multiple sclerosis (MS) progression reveal that disability accumulation can start early in the disease course. Aging in MS is increasingly recognized as a key factor for disease progression and disability accrual. We evaluate the prognostic impact of age in a cohort of patients experiencing a first demyelinating event (FDE), using a variety of disability outcomes, including some not previously assessed in age-specific studies. METHODS: Patients aged 18-50 years, assessed within 3 months from the FDE, were prospectively included since 1994 and categorized into 3 age groups: 18-29, 30-39, and 40-50 years. Relapse-associated worsening (RAW) at FDE, annualized relapse rate, and EDSS trajectories during follow-up were compared across age groups. Cox regression analyses adjusted for sex, comorbidities, and time exposed to very high-efficacy drugs were performed to assess the risk of achieving the following outcomes: time to reach McDonald 2017 criteria, first relapse, recurrent RAW, >2 new T2 brain lesions/year, first progression independent of relapse activity (PIRA), confirmed disability accumulation (CDA), and confirmed EDSS score 3.0. Patient-reported outcome measures were also analyzed. RESULTS: A total of 1,170 patients were included (median age 32 years; 69% female). The 40-50 group had a higher proportion of RAW at FDE (34% vs 25% and 29%; p = 0.031) and less time exposed to very high-efficacy treatments (p < 0.001) than the 30-39 and 18-29 groups, respectively. EDSS trajectories in the 40-50 group displayed a greater annual increase in the EDSS score compared with the 18-29 group (β 0.019 [95% CI 0.0001; 0.0387]). Cox analyses (HR; 95% CI) showed that the 40-50 group was at lower risk to reach McDonald 2017 criteria (0.80; 0.67-0.96), first relapse (0.59; 0.47-0.74), recurrent RAW (0.51; 0.31-0.86), or >2 new T2 brain lesions/year (0.39; 0.30-0.52), but at a higher risk of CDA (1.49; 1.16-1.97), PIRA (2.48; 1.88-3.27), and EDSS score 3.0 (1.50; 1.05-2.12), than the 18-29 group. Different functional and well-being variables were more affected in the 40-50 group, compared with 30-39 and 18-29 groups (p values< 0.05). DISCUSSION: Patients with a FDE at 40-50 years exhibit less inflammatory outcomes compared with younger patients and reach outcomes more closely related to neurodegeneration despite the lower disease activity.
引用
- Cobo-Calvo A, Carbonell-Mirabent P, Tur C, et al. Age-Related Disability Outcomes After a First Demyelinating Event. Neurology. 2025. PMID: 39903901. doi:10.1212/WNL.0000000000210305
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。